This study focuses on patients who have been diagnosed with high-risk rhabdomyosarcoma (RMS). RMS is a type of cancer that occurs in the soft tissues of the body (like the muscles). RMS is considered high-risk when it has spread to other areas of the body. The purpose of the study is to evaluate whether an experimental drug called vinorelbine can be given safely in combination with the standard chemotherapy drugs vincristine, dactinomycin, and cyclophosphamide (together called VINO-AC with vincristine). Vinorelbine is in the same class of drugs as vincristine and stops cancer cells from dividing. Researchers also aim to determine whether they can improve outcomes for patients with high-risk RMS by extending the traditional treatment to include a treatment phase called maintenance therapy. All participants will receive maintenance therapy, during which they will receive vinorelbine and cyclophosphamide.
What is the full name of this clinical trial?
ARST2031: A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide vs Vincristine, Dactinomycin and Cyclophosphamide plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma *^